Revolution Medicines' Europe efforts point to a possible solo launch for its pancreatic cancer drug

Reuters reports Revolution Medicines is laying the groundwork for a broad European commercial rollout of its pancreatic cancer drug. The efforts suggest it may try to bring the therapy to market without relying on a local partner to sell it.